Nirmatrelvir y ritonavir. Información para pacientes
Date
2022Document Number
OPS/HSS/MT/COVID-19/22-0035
Metadata
Show full item recordOther Language Versions
Abstract
La Organización Panamericana de la Salud presenta este díptico con el fin de informar a los pacientes y al público general sobre la combinación de nirmatrelvir con ritonavir. Este tratamiento, que requiere prescripción médica, está indicado para casos de leves a moderados en personas con prueba confirmatoria positiva que tengan un riesgo alto de progresión a cuadro grave o crítico y de hospitalización.
Collections
This notice should be preserved along with the article's original URL.Attribution-NonCommercial-ShareAlike 3.0 IGO
Related items
Showing items related by title, author, creator and subject.
-
Rosa, Sandro G. Viveiros; Santos, Wilson C. (2020)[ABSTRACT]. The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were ...
-
Mello, Vinícius de; Pereira, Vinícius de Paula; Rodrigues, João Paulo Vilela; Penteado, Suelem Tavares da Silva; Pereira, Leonardo Régis Leira; Varallo, Fabiana Rossi (2022)[RESUMO]. Objetivo. Identificar eventos adversos no sistema nervoso central (SNC) potencialmente associados ao uso de medicamentos para profilaxia ou tratamento da COVID-19, bem como caracterizar os indivíduos acometidos. ...
-
Pan American Health Organization; Health Systems and Services (HSS) (PAHOUnited StatesWashington, D.C., 2022)The purpose of this publication is to make health professionals aware of the potential benefits and risks of the combination of nirmatrelvir with ritonavir in the treatment of COVID-19, since, compared to other treatments, ...